A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma Journal Articles

Overview
Research
Identity
Additional Document Info
View All

authors

Han, Ming
Murugesan, Alli
Bahlis, Nizar J
Song, Kevin
White, Darrell
Chen, Christine
Seftel, Matthew D
Howsen-Jan, Kang
Reece, Donna
Stewart, Keith
Xie, Yagang
Hay, Annette E
Shepherd, Lois
Djurfeldt, Marina
Zhu, Liting
Meyer, Ralph
Chen, Bingshu E
Reiman, Tony

status

published

publication date

August 4, 2016

has subject area

1102 Cardiorespiratory Medicine and Haematology (FoR)
1103 Clinical Sciences (FoR)
1114 Paediatrics and Reproductive Medicine (FoR)
Antineoplastic Combined Chemotherapy Protocols (MeSH)
Canada (MeSH)
Genetic Predisposition to Disease (MeSH)
Hematopoietic Stem Cell Transplantation (MeSH)
Humans (MeSH)
Immunology (Science Metrix)
Maintenance Chemotherapy (MeSH)
Melphalan (MeSH)
Multiple Myeloma (MeSH)
Pharmacogenomic Testing (MeSH)
Polymorphism, Single Nucleotide (MeSH)
Prednisone (MeSH)
Randomized Controlled Trials as Topic (MeSH)
Survival Analysis (MeSH)
Thalidomide (MeSH)
Transplantation, Autologous (MeSH)

published in

Blood Journal